About

Topical ruxolitinib is used for atopic dermatitis (eczema) and nonsegmental vitiligo. The brand name is Opzelura, and it is a cream that is applied thinly twice a day. Do not exceed the maximum dose of (1 x 60-gram tube/week or 1 x 100-gram tube/week).

Ruxolitinib works by blocking specific proteins called JAK1 and JAK2 that send "grow and multiply" signals to blood cells and immune cells. By stopping these signals, ruxolitinib cream decreases harmful inflammation in skin conditions such as atopic dermatitis and nonsegmental vitiligo by suppressing inflammatory cytokines. It belongs to the drug class called kinase inhibitors.

Ruxolitinib first gained FDA approval on November 16, 2011, as the oral tablet formulation, under the brand name Jakafi. Topical ruxolitinib was FDA approved on September 21, 2021, under the brand name Opzelura. There is no generic ruxolitinib.